Fecal Microbiota Transplantation & Cirrhosis
Long-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis.
Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis.
Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.
Alcohol, liver disease and the gut microbiota.
Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
Liver-Microbiome Axis in Health and Disease.
Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant.
Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.
Fecal microbiota transplantation for hepatic encephalopathy: Ready for prime time?
Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
The Transplantation of Fecal Microbiota for Cirrhotic Patients.
Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis.
Is it reasonable to perform Fecal Microbiota Transplantation for recurrent Clostridium difficile Infection in patients with liver cirrhosis?
Update on the Therapeutic Management of Hepatic Encephalopathy.
Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease.
Targeting the gut-liver axis in liver disease.
Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.
Alcohol Addiction, Gut Microbiota, and Alcoholism Treatment: A Review.
Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant.
Alcohol or Gut Microbiota: Who Is the Guilty?
Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Acute-on-chronic liver failure in patients with alcohol-related liver disease.
The effect of fecal microbiota transplantation on Hepatic myelopathy: A case report.
Patients With Cirrhosis Require More Fecal Microbiota Capsules to Cure Refractory and Recurrent Clostridium difficile Infections.
Intestinal microbiota in liver disease.
Role of Microbiota in Pathogenesis and Management of Viral Hepatitis.
Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis.
PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial.
Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant.
Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic gammadelta T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Regulating Intestinal Microbiota in the Prevention and Treatment of Alcohol-Related Liver Disease.
Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.
Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.
Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis.
Microbiota, a key player in alcoholic liver disease.
Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy-A case series.
Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.
Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?
Targeting Dysbiosis for the Treatment of Liver Disease.
Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis.
Gut microbiota in cirrhotic liver transplant candidates.
Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease.
Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation.
Healthy donor faecal transplant for corticosteroid non-responsive severe alcoholic hepatitis.
Chronic Liver Diseases and the Microbiome: Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.
The relevance of intestinal dysbiosis in liver transplant candidates.